Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis

NCT05569759 is registered in ClinicalTrials.gov with Kezar Life Sciences, Inc. as lead sponsor.

NCT NCT05569759
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05569759 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis
Lead sponsor
Kezar Life Sciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 23, 2023
Completion date
April 30, 2025
Enrollment
24 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hepatitis